<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>2016 on CityU Wang Lab</title>
    <link>/tags/2016/</link>
    <description>Recent content in 2016 on CityU Wang Lab</description>
    <generator>Hugo -- gohugo.io</generator>
    <language>en-us</language>
    <lastBuildDate>Thu, 17 Nov 2016 13:07:31 +0200</lastBuildDate>
    
	<atom:link href="/tags/2016/index.xml" rel="self" type="application/rss+xml" />
    
    
    <item>
      <title>A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.</title>
      <link>/publications/1604onco_wx/</link>
      <pubDate>Thu, 17 Nov 2016 13:07:31 +0200</pubDate>
      
      <guid>/publications/1604onco_wx/</guid>
      <description>Author Fessler E, Jansen M, De Sousa E Melo F, Zhao L, Prasetyanti PR, Rodermond H, Kandimalla R, Linnekamp JF, Franitza M, van Hooff SR, de Jong JH, Oppeneer SC, van Noesel CJM, Dekker E, Stassi G, Wang X*, Medema JP*, and Vermeulen L*.
Oncogene 2016, doi:10.1038/onc.2016.134
Abstract Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classification and treatment of this malignancy. There is no common genetic molecular feature that would allow for the identification of patients at risk for developing recurrences and thus selecting patients who would benefit from more stringent therapies still poses a major clinical challenge.</description>
    </item>
    
    <item>
      <title>A multidimensional network approach reveals microRNAs as determinants of the mesenchymal colorectal cancer subtype.</title>
      <link>/blog/1604onco_wx/</link>
      <pubDate>Thu, 17 Nov 2016 13:07:31 +0200</pubDate>
      
      <guid>/blog/1604onco_wx/</guid>
      <description>Author Fessler E, Jansen M, De Sousa E Melo F, Zhao L, Prasetyanti PR, Rodermond H, Kandimalla R, Linnekamp JF, Franitza M, van Hooff SR, de Jong JH, Oppeneer SC, van Noesel CJM, Dekker E, Stassi G, Wang X*, Medema JP*, and Vermeulen L*.
Oncogene 2016, doi:10.1038/onc.2016.134
Abstract Colorectal cancer (CRC) is a heterogeneous disease posing a challenge for accurate classification and treatment of this malignancy. There is no common genetic molecular feature that would allow for the identification of patients at risk for developing recurrences and thus selecting patients who would benefit from more stringent therapies still poses a major clinical challenge.</description>
    </item>
    
    <item>
      <title>The consensus molecular subtypes of colorectal cancer</title>
      <link>/publications/1602nm_wx/</link>
      <pubDate>Sun, 13 Mar 2016 13:07:31 +0200</pubDate>
      
      <guid>/publications/1602nm_wx/</guid>
      <description>Author Guinney J†, Dienstmann R†, Wang X†, de Reyniès A†, Schlicker A†, Soneson C†, Marisa L†, Roepman P†, Nyamundanda G†, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L &amp;amp; Sabine Tejpar</description>
    </item>
    
    <item>
      <title>The consensus molecular subtypes of colorectal cancer</title>
      <link>/blog/1602nm_wx/</link>
      <pubDate>Sun, 13 Mar 2016 13:07:31 +0200</pubDate>
      
      <guid>/blog/1602nm_wx/</guid>
      <description>Author Guinney J†, Dienstmann R†, Wang X†, de Reyniès A†, Schlicker A†, Soneson C†, Marisa L†, Roepman P†, Nyamundanda G†, Angelino P, Bot BM, Morris JS, Simon IM, Gerster S, Fessler E, De Sousa E Melo F, Missiaglia E, Ramay H, Barras D, Homicsko K, Maru D, Manyam GC, Broom B, Boige V, Perez-Villamil B, Laderas T, Salazar R, Gray JW, Hanahan D, Tabernero J, Bernards R, Friend SH, Laurent-Puig P, Medema JP, Sadanandam A, Wessels L, Delorenzi M, Kopetz S, Vermeulen L &amp;amp; Sabine Tejpar</description>
    </item>
    
    <item>
      <title>Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.</title>
      <link>/publications/1603sci_wx/</link>
      <pubDate>Fri, 15 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/publications/1603sci_wx/</guid>
      <description>Author Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell APW, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C, Kurita R, Nakamura Y, Xu J, Higgs DR, Crossley M, Bauer DE, Orkin SH, Kharchenko PV, Maeda T
**Science ** 2016, doi:10.1126/science.aad3312.
Abstract Genes encoding human β-type globin undergo a developmental switch from embryonic to fetal to adult-type expression. Mutations in the adult form cause inherited hemoglobinopathies or globin disorders, including sickle cell disease and thalassemia.</description>
    </item>
    
    <item>
      <title>Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.</title>
      <link>/blog/1603sci_wx/</link>
      <pubDate>Fri, 15 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/blog/1603sci_wx/</guid>
      <description>Author Masuda T, Wang X, Maeda M, Canver MC, Sher F, Funnell APW, Fisher C, Suciu M, Martyn GE, Norton LJ, Zhu C, Kurita R, Nakamura Y, Xu J, Higgs DR, Crossley M, Bauer DE, Orkin SH, Kharchenko PV, Maeda T
Science 2016, doi:10.1126/science.aad3312.
Abstract Genes encoding human β-type globin undergo a developmental switch from embryonic to fetal to adult-type expression. Mutations in the adult form cause inherited hemoglobinopathies or globin disorders, including sickle cell disease and thalassemia.</description>
    </item>
    
    <item>
      <title>The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains</title>
      <link>/publications/1601gd_wx/</link>
      <pubDate>Mon, 11 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/publications/1601gd_wx/</guid>
      <description>Author Alekseyenko AA†, Walsh EM†, Wang X†, Grayson AR, Hsi PT, Kharchenko PV, Kuroda MI, and French CA
Genes Dev 2015, doi:10.1101/gad.267583.115.
Abstract NUT midline carcinoma (NMC), a subtype of squamous cell cancer, is one of the most aggressive human solid malignancies known. NMC is driven by the creation of a translocation oncoprotein, BRD4-NUT, which blocks differentiation and drives growth of NMC cells. BRD4-NUT forms distinctive nuclear foci in patient tumors, which we found correlate with ∼100 unprecedented, hyperacetylated expanses of chromatin that reach up to 2 Mb in size.</description>
    </item>
    
    <item>
      <title>The oncogenic BRD4-NUT chromatin regulator drives aberrant transcription within large topological domains</title>
      <link>/blog/1601gd_wx/</link>
      <pubDate>Mon, 11 Jan 2016 13:07:31 +0200</pubDate>
      
      <guid>/blog/1601gd_wx/</guid>
      <description>Author Alekseyenko AA†, Walsh EM†, Wang X†, Grayson AR, Hsi PT, Kharchenko PV, Kuroda MI, and French CA
Genes Dev 2015, doi:10.1101/gad.267583.115.
Abstract NUT midline carcinoma (NMC), a subtype of squamous cell cancer, is one of the most aggressive human solid malignancies known. NMC is driven by the creation of a translocation oncoprotein, BRD4-NUT, which blocks differentiation and drives growth of NMC cells. BRD4-NUT forms distinctive nuclear foci in patient tumors, which we found correlate with ∼100 unprecedented, hyperacetylated expanses of chromatin that reach up to 2 Mb in size.</description>
    </item>
    
  </channel>
</rss>